Publications

Antimicrobial activity of omadacycline tested against clinical bacterial isolates collected from hospitals in China, including Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013-2016). Lead author HS Sader, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0102

Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101. Lead author: MD Huband, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
#P0157

Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Lead author: MA Pfaller, presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0323

Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta-lactam resistance mechanisms. Lead author: M Castanheira presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, April 21-24, Madrid, Spain
# P0093

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). by Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M and Sader HS published in Diagn. Microbiol. Infect. Dis. 2018; 91 (1): 77-84

Assessment of ceftazidime-avibactam 30/20 µg disk content versus MIC results when tested against Enterobacteriaceae and Pseudomonas aeruginosa. by Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK and Jones RN published in J. Clin. Microbiol. 2018 in press

Dalbavancin in vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in United States and European hospitals (2011-2016). by Pfaller MA, Flamm RK, Castanheira M, Sader HS and Mendes RE published in Int. J. Antimicrob. Agents. 2018; 51 (4): 608-611

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016. by Pfaller MA, Huband MD, Shortridge D and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (4): e02327

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018 in press

Fungemia surveillance in Denmark demonstrates emergence of Candida non-albicans, higher antifungal usage and resistance rates when compared to other nations. by Castanheira M published in J. Clin. Microbiol. 2018; 56 (4): e01907

Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015. by Castanheira M, Duncan LR, Mendes RE, Sader HS and Shortridge D published in Antimicrob. Agents Chemother. 2018; 62 (3): e02125

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). by Pfaller MA, Huband MD, Streit J, Flamm RK and Sader HS Int. J. Antimicrob. Agents 2018; 51 (6): 848-853

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M. Int. J. Antimicrob. Agents. 2018: 52 (2); 144-150

In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: Results from seven years of the AWARE Surveillance Program (2010 to 2016). by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS published in Antimicrob. Agents Chemother. 2018 62 (2): e01555

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M publishedin Int. J. Antimicrob. Agents 2018 in press

Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to flycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers. by Sader HS, Mendes RE, Duncan LR, Pfaller MA and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (3): e02397

The application of in vitro surveillance data for antibacterial dose selection. by Flamm RK, Sader HS, Castanheira M and Jones RN published in Curr Opin Pharmacol 2017; 36:130-138

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates. by Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK and Castanheira M published in Antimicrob. Agents Chemother. 2017; 62 (1): e01856

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility. by Shortridge D, Pfaller MA, Castanheira M and Flamm RK published in Microb. Drug Resist. 2018; 24 (5): 563-577

Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016). by Sader HS, Castanheira M, Shortridge D, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (11): e01045

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M and Flamm RK published in Braz. J. Infect. Dis. 2017; 21 (6): 627-637

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): Report from an antimicrobial surveillance program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Castanheira M and Flamm RK Int. J. Antimicrob. Agents. 2018; 51 (2): 181-189

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018; 90 (2): 143-147

Case report of transient mcr-1-haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California. by Le J, Turner N, Deshpande LM, Davis AP and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2017; 89 (4): 303-304

In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) when tested against contemporary clinical bacteria from a global surveillance program. by Flamm RK, Rhomberg PR and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (12): e01230

Dilution factor of quantitative bacterial cultures obtained by bronchoalveolar lavage in patients with ventilator-associated bacterial pneumonia: Implications for optimal antimicrobial therapy ventilator-associated bacterial pneumonia study group. by Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo Torre CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M and Berman C published in Antimicrob. Agents Chemother. 2018; in press

Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. by Castanheira M, Duncan LR, Rhomberg PR and Sader HS published in Diagn. Microbiol. Infect. Dis.2017; 89 (4): 305-309

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014-2016), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1215

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers (2013-2016), Lead Author: Sader HS, presented at IDWeek 2017, October 4-7, San Diego, CA, USA
Poster #1232

Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe during 2014-2016 as Part of a Global Surveillance Program, Lead author: Flamm RK, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1222

Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010-2016), Lead author: Pfaller MA, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1239

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1216

Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing, Lead author: Castanheira, M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1235

Ceftobiprole Activity When Tested against Contemporary Bacteria Causing Bloodstream Infections in the US (2016), Lead author: Flamm RK, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1205

Yearly Trends of Antimicrobial Nonsusceptibility among Streptococcus pneumoniae Serotypes Causing Infection in Adult Patients in the United States (2009-2015), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1496

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States Medical Centers Stratified by Infection Type (2015-2016), Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1237

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Community-Acquired Bacterial Respiratory Tract Infection Isolates (2014-2106): Results from the SENTRY Antimicrobial Surveillance Program, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1208

Analysis of Oritavancin Activity Against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008-2016), Lead author: Pfaller MA, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1207

Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States Medical Centers (2011-2016), Lead Author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1221

Distributions and Annual Changes of Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients: 8 Years of US Surveillance (2009-2016), Lead author: Arends SJR, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1500

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-Negative Organisms Causing Bloodstream Infections Worldwide, Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1226

Activity of Meropenem-Vaborbactam (VABOMERE^TM) against Enterobacteriaceae Isolates carrying bla_kpc Collected Worldwide, Lead author: Castanheira, M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1234

In Vitro Activity of Omadacycline and Comparator Compounds against Gram-Positive Isolates Collected in the US During 2016 as Part of a Global Surveillance Program, Lead author: Huband MD, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1223

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs Non-ICU Respiratory Isolates Collected in US Medical Centers, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1198

Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014-2016), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1210

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012-2016 as Part of a Global Surveillance Program, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1202

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates, Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1233

Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States Medical Centers, Lead author: Sader HS, presented at IDWeek 2017, October 4-7, San Diego, CA, USA
Poster #1238

Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Gram-Negative Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #331

Sustained In Vitro Activity of Linezolid and Evolving Resistance Mechanisms: Summary of the Zyvox^® Annual Appraisal of Potency and Spectrum Program for 2016, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #329